Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-09-29
DOI
10.3389/fimmu.2017.01215
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.
- (2017) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.
- (2017) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
- (2017) Cynthia L. Gay et al. JOURNAL OF INFECTIOUS DISEASES
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
- (2016) Anushree C. Shirali et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
- (2016) Laura C Cappelli et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155
- (2016) Baofu Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Managing Adverse Events With Immune Checkpoint Agents
- (2016) Ramona Dadu et al. CANCER JOURNAL
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
- (2016) Meromit Singer et al. CELL
- Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators
- (2016) Hilmar Weinmann ChemMedChem
- Immune-Related Adverse Events From Immune Checkpoint Inhibitors
- (2016) KA Marrone et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Side-effects of checkpoint inhibitor-based combination therapy
- (2016) Hampig R. Kourie et al. CURRENT OPINION IN ONCOLOGY
- Checkpoint inhibitors and gastrointestinal immune-related adverse events
- (2016) Simon Pernot et al. CURRENT OPINION IN ONCOLOGY
- Immune-mediated respiratory adverse events of checkpoint inhibitors
- (2016) Samer Tabchi et al. CURRENT OPINION IN ONCOLOGY
- From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway
- (2016) Mei-Miao Zhan et al. DRUG DISCOVERY TODAY
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- (2016) V.R. Belum et al. EUROPEAN JOURNAL OF CANCER
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
- (2016) Luuk van Hooren et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)
- (2016) Tryfon Zarganes-Tzitzikas et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
- (2016) Andrea Schietinger et al. IMMUNITY
- T Cell Factor 1-Expressing Memory-like CD8 + T Cells Sustain the Immune Response to Chronic Viral Infections
- (2016) Daniel T. Utzschneider et al. IMMUNITY
- Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses
- (2016) Alison Taylor et al. IMMUNITY
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- Genetic and Epigenetic Regulation of PD-1 Expression
- (2016) Alexander P. R. Bally et al. JOURNAL OF IMMUNOLOGY
- Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase
- (2016) Takashi Inozume et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Anti-PD1-induced collagenous colitis in a melanoma patient
- (2016) Barouyr Baroudjian et al. MELANOMA RESEARCH
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
- (2016) Alena Gros et al. NATURE MEDICINE
- Damage-associated molecular patterns in cancer: a double-edged sword
- (2016) C Hernandez et al. ONCOGENE
- Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
- (2016) Katrin Klocke et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The epigenetic landscape of T cell exhaustion
- (2016) D. R. Sen et al. SCIENCE
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- (2016) I. Tirosh et al. SCIENCE
- Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab
- (2016) Jeremy W. Vandiver et al. Targeted Oncology
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
- (2016) Krzysztof M. Zak et al. Oncotarget
- TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection
- (2016) Glen M. Chew et al. PLoS Pathogens
- Ipilimumab-induced colitis: experience from a tertiary referral center
- (2016) Anthony O’Connor et al. Therapeutic Advances in Gastroenterology
- Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update
- (2016) Masatoshi Kudo Liver Cancer
- Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma
- (2015) Fiona Wightman et al. AIDS
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent
- (2015) Robert G. Gish et al. ANTIVIRAL RESEARCH
- Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis
- (2015) Olga Venditti et al. BMC CANCER
- A Threshold Level of Intratumor CD8 + T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
- (2015) Shin Foong Ngiow et al. CANCER RESEARCH
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial
- (2015) A. Legat et al. CLINICAL CANCER RESEARCH
- The Transcription Factor NFAT Promotes Exhaustion of Activated CD8 + T Cells
- (2015) Gustavo J. Martinez et al. IMMUNITY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+T cells
- (2015) Pamela M. Odorizzi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+T-Cell Population in Elite Controllers
- (2015) Carolina Pombo et al. JOURNAL OF INFECTIOUS DISEASES
- A Jekyll and Hyde Profile: Type 1 Interferon Signaling Plays a Prominent Role in the Initiation and Maintenance of a Persistent Virus Infection
- (2015) Michael B. A. Oldstone JOURNAL OF INFECTIOUS DISEASES
- Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
- (2015) Anna Śledzińska et al. Molecular Oncology
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Big opportunities for small molecules in immuno-oncology
- (2015) Jerry L. Adams et al. NATURE REVIEWS DRUG DISCOVERY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection
- (2015) P. Penaloza-MacMaster et al. SCIENCE
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- T cell exhaustion during persistent viral infections
- (2015) Shannon M. Kahan et al. VIROLOGY
- T-cell exhaustion in the tumor microenvironment
- (2015) Y Jiang et al. Cell Death & Disease
- PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
- (2015) Nikolaos Patsoukis et al. Nature Communications
- Ipilimumab-Induced Encephalopathy with a Reversible Splenial Lesion
- (2015) R. M. Conry et al. Cancer Immunology Research
- Ipilimumab-Associated Retinopathy
- (2015) Jonathan Crews et al. Ophthalmic Surgery Lasers & Imaging Retina
- Inhibitory Receptors Beyond T Cell Exhaustion
- (2015) Silvia A. Fuertes Marraco et al. Frontiers in Immunology
- PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity
- (2015) Tong Seng Lim et al. OncoImmunology
- Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma
- (2015) Hans A. Schlößer et al. OncoImmunology
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
- (2015) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma
- (2014) Betty S. Jiang et al. ANNALS OF SURGICAL ONCOLOGY
- Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
- (2014) Tai Hato et al. HEPATOLOGY
- The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection
- (2014) Matthew M. Staron et al. IMMUNITY
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection
- (2014) Pablo Penaloza-MacMaster et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- (2014) Rituparna Das et al. JOURNAL OF IMMUNOLOGY
- Expansion of Dysfunctional Tim-3–Expressing Effector Memory CD8+T Cells during Simian Immunodeficiency Virus Infection in Rhesus Macaques
- (2014) Tsuyoshi Fujita et al. JOURNAL OF IMMUNOLOGY
- At the Bedside: Adoptive cell therapy for melanoma-clinical development
- (2014) Jeffrey S. Weber JOURNAL OF LEUKOCYTE BIOLOGY
- Ipilimumab in patients with cancer and the management of dermatologic adverse events
- (2014) Mario E. Lacouture et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial
- (2014) Emanuela Romano et al. Journal of Translational Medicine
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- HBV and the immune response
- (2014) Carlo Ferrari LIVER INTERNATIONAL
- Levels of CD56+TIM-3- Effector CD8 T Cells Distinguish HIV Natural Virus Suppressors from Patients Receiving Antiretroviral Therapy
- (2014) Bhawna Poonia et al. PLoS One
- Inhibitory Phenotype of HBV-Specific CD4+ T-Cells Is Characterized by High PD-1 Expression but Absent Coregulation of Multiple Inhibitory Molecules
- (2014) Bijan Raziorrouh et al. PLoS One
- CD127 Expression, Exhaustion Status and Antigen Specific Proliferation Predict Sustained Virologic Response to IFN in HCV/HIV Co-Infected Individuals
- (2014) Hassen Kared et al. PLoS One
- Animal models for viral infection and cell exhaustion
- (2014) Colleen S. McGary et al. Current Opinion in HIV and AIDS
- T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection
- (2014) Marcus Buggert et al. PLoS Pathogens
- Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”
- (2014) Lucia Gelao et al. Toxins
- Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
- (2014) M. M. Berrien-Elliott et al. Cancer Immunology Research
- Opportunistic infections in patients treated with immunotherapy for cancer
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Expression of inhibitory markers is increased on effector memory T cells during hepatitis C virus/HIV coinfection as compared to hepatitis C virus or HIV monoinfection
- (2013) Banishree Saha et al. AIDS
- PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
- (2013) J. Fourcade et al. CANCER RESEARCH
- Characteristics of splenic CD8+T cell exhaustion in patients with hepatitis C
- (2013) K. Sumida et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression
- (2013) H. Tang et al. CLINICAL CANCER RESEARCH
- Liver Environment and HCV Replication Affect Human T-Cell Phenotype and Expression of Inhibitory Receptors
- (2013) Daniela C. Kroy et al. GASTROENTEROLOGY
- Ipilimumab Administration in Patients With Advanced Melanoma and Hepatitis B and C
- (2013) Anupa Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-Induced Hepatitis C Viral Suppression
- (2013) Steven Minter et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complementary Role of HCV and HIV in T-Cell Activation and Exhaustion in HIV/HCV Coinfection
- (2013) Thijs Feuth et al. PLoS One
- A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
- (2013) David Gardiner et al. PLoS One
- PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral Loads
- (2013) Edward Seung et al. PLoS One
- Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)
- (2013) M. J. Fuller et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells
- (2013) Amandine Legat et al. Frontiers in Immunology
- Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection
- (2012) S. Elahi et al. BLOOD
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Blockade of Tim-3 signaling restores the virus-specific CD8+T-cell response in patients with chronic hepatitis B
- (2012) Wei Wu et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- PD-1 is a novel regulator of human B-cell activation
- (2012) Marie-Laure Thibult et al. INTERNATIONAL IMMUNOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibitory Receptors on Lymphocytes: Insights from Infections
- (2012) P. M. Odorizzi et al. JOURNAL OF IMMUNOLOGY
- Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
- (2012) Wenshi Wang et al. Journal of Translational Medicine
- Progressive Loss of Memory T Cell Potential and Commitment to Exhaustion during Chronic Viral Infection
- (2012) J. M. Angelosanto et al. JOURNAL OF VIROLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
- (2012) Lukas Baitsch et al. PLoS One
- Tim-3 Negatively Regulates Cytotoxicity in Exhausted CD8+ T Cells in HIV Infection
- (2012) Ali Sakhdari et al. PLoS One
- Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection
- (2012) Gaia Nebbia et al. PLoS One
- Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection
- (2012) M. A. Paley et al. SCIENCE
- CD160 and PD-1 Co-Expression on HIV-Specific CD8 T Cells Defines a Subset with Advanced Dysfunction
- (2012) Yoav Peretz et al. PLoS Pathogens
- PD-1 and BTLA and CD8+T-cell “exhaustion” in cancer
- (2012) Cara Haymaker et al. OncoImmunology
- Serum miR-122 as a Biomarker of Necroinflammation in Patients With Chronic Hepatitis C Virus Infection
- (2011) Verena Bihrer et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
- (2011) J. Fourcade et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma
- (2011) J. J. Luke et al. CLINICAL CANCER RESEARCH
- Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
- (2011) Lukas Baitsch et al. JOURNAL OF CLINICAL INVESTIGATION
- Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic Melanoma
- (2011) Matthew M. Burke et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulatory T Cells Selectively Control CD8+ T Cell Effector Pool Size via IL-2 Restriction
- (2011) W. Kastenmuller et al. JOURNAL OF IMMUNOLOGY
- Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection
- (2011) Charlly Kao et al. NATURE IMMUNOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Protective HIV-specific CD8+ T cells evade Treg cell suppression
- (2011) Shokrollah Elahi et al. NATURE MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma
- (2011) Verena Bihrer et al. PLoS One
- CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis
- (2011) A. McNally et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer
- (2010) Yan Zhang et al. Cellular & Molecular Immunology
- HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression
- (2010) Bahareh Vali et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The CD4-like molecule LAG-3, biology and therapeutic applications
- (2010) Sophie Sierro et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function
- (2010) Bijan Raziorrouh et al. HEPATOLOGY
- BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination
- (2010) Laurent Derré et al. JOURNAL OF CLINICAL INVESTIGATION
- Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity
- (2010) Rachel H. McMahan et al. JOURNAL OF CLINICAL INVESTIGATION
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation
- (2010) Jun Yu et al. Molecular Cancer
- Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis
- (2010) Jian Xu et al. MOLECULAR CARCINOGENESIS
- Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF
- (2010) Michael Quigley et al. NATURE MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment
- (2010) Guocai Lv et al. Virology Journal
- Targeting microRNA-122 to Treat Hepatitis C Virus Infection
- (2010) Catherine L. Jopling Viruses-Basel
- Coexpression of PD-1, 2B4, CD160 and KLRG1 on Exhausted HCV-Specific CD8+ T Cells Is Linked to Antigen Recognition and T Cell Differentiation
- (2010) Bertram Bengsch et al. PLoS Pathogens
- PD-1 on dendritic cells impedes innate immunity against bacterial infection
- (2009) S. Yao et al. BLOOD
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- Progressive CD127 down-regulation correlates with increased apoptosis of CD8 T cells during chronic HIV-1 infection
- (2009) Shu-Ye Zhang et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B
- (2009) Paola Fisicaro et al. GASTROENTEROLOGY
- A Role for the Transcriptional Repressor Blimp-1 in CD8+ T Cell Exhaustion during Chronic Viral Infection
- (2009) Haina Shin et al. IMMUNITY
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
- (2009) J. Fourcade et al. JOURNAL OF IMMUNOLOGY
- Tissue-Specific Differences in PD-1 and PD-L1 Expression during Chronic Viral Infection: Implications for CD8 T-Cell Exhaustion
- (2009) S. D. Blackburn et al. JOURNAL OF VIROLOGY
- Negative Immune Regulator Tim-3 Is Overexpressed on T Cells in Hepatitis C Virus Infection and Its Blockade Rescues Dysfunctional CD4+ and CD8+ T Cells
- (2009) L. Golden-Mason et al. JOURNAL OF VIROLOGY
- Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade
- (2009) Nobuhiro Nakamoto et al. PLoS Pathogens
- Phenotype and function of human T lymphocyte subsets: Consensus and issues
- (2008) Victor Appay et al. CYTOMETRY PART A
- Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmentalization
- (2008) Nobuhiro Nakamoto et al. GASTROENTEROLOGY
- Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
- (2008) R. Brad Jones et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Enhancing SIV-specific immunity in vivo by PD-1 blockade
- (2008) Vijayakumar Velu et al. NATURE
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
- (2008) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade
- (2008) S. D. Blackburn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
- Regulatory T Cells: Mechanisms of Differentiation and Function
- (2007) Steven Z. Josefowicz et al. Annual Review of Immunology
- PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients
- (2007) Guoping Peng et al. MOLECULAR IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started